Financial Statements

Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. (APLS)


Cash Flow Statement

Download APLS income statement Download APLS income statement
Year 2015201620172018
Depreciation & Amortization ----
Stock-based compensation 0.551.085.427.73
Operating Cash Flow -18.86-26.00-46.60-131.24
Capital Expenditure ----
Acquisitions and disposals ----
Investment purchases and sales ----
Investing Cash Flow ----
Insurance (repayment) of debt ----
Insurance (buybacks) of shares ----
Dividend payments ----
Financing Cash Flow 41.2414.86197.38131.90
Effect of forex changes on cash ----0.04
Net cash flow / Change in cash 22.38-11.14150.780.62
Free Cash Flow -18.86-26.00-46.60-131.24
Net Cash/Marketcap

Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.